Draft Guidance on Estradiol; Norethindrone acetate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Estradiol; Norethindrone acetate

Dosage Form; Route: Film, extended release; transdermal

Recommended Studies: Three studies (Note: Studies on one strength of the drug product may not be used to support the approval of the other strength. All three studies should be conducted independently for 0.05;0.14 mg/24 hr and 0.05;0.25 mg/24 hr strengths.

1. Type of study: Bioequivalence (BE) study with pharmacokinetic (PK) endpoints
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 0.05;0.14 mg/24 hr or 0.05;0.25 mg/24 hr
   Subjects: Non-smoking, postmenopausal women with no contraindication to estrogen therapy

   Additional comments:
   - In this document, this dosage form is referred to as a transdermal delivery system (TDS) and includes products that may be described elsewhere or known as patches or extended release films.
   - Unless otherwise justified, the estradiol; norethindrone acetate TDS should be applied to the same anatomical site on all subjects, as recommended for dosing in the approved labeling for the reference listed drug (RLD) product, and worn for 3.5 days (84 hours). Applicants should randomize subjects to receive either the test or RLD product in a given study period. When possible, the TDS administered in the second study period should be applied to the same anatomical site as in the first study period, but on the contralateral side of the body.
   - Contact of the TDS with the skin is essential for the in vivo performance of the TDS, and the PK may be altered when a TDS loses its adherence to the skin. Therefore, the adhesion of each TDS should be monitored and recorded throughout the PK study. The PK samples should be collected and analyzed from all subjects at all sampling times regardless of the adhesion scores of the TDS. Provisions should be included in the study protocol to ensure that deliberate actions with the intent to re-apply a detached area of the TDS, to apply pressure to the TDS, or to reinforce TDS adhesion with the skin (e.g., overlays) are avoided throughout the study.
   - The applicant should follow FDA’s current thinking in the guidance “Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA” for the design and conduct of the PK BE study.
**Analytes to measure (in appropriate biological fluid):** Estradiol and norethindrone in plasma. An average baseline correction is obtained by averaging the 3 pre-application sampling times (-1, -0.5 and 0 hours).

**Bioequivalence based on (90% CI):** Estradiol (using both baseline corrected and uncorrected data) and norethindrone.

**Waiver request of in vivo testing:** Not applicable.

**Dissolution test method and sampling times:** Comparative dissolution testing should be conducted on 12 dosage units each, of the test and RLD products. Information on a dissolution method for this drug product can be found on the FDA Dissolution Methods web site, accessible at: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/).

---

2. **Type of study:** Adhesion study  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 0.05;0.14 mg/24 hr or 0.05;0.25 mg/24 hr  
   **Subjects:** Non-smoking, postmenopausal women with no contraindication to estrogen therapy

   **Additional comments:**
   - The applicant may elect to evaluate the PK BE (study 1) and the adhesion (study 2) in a single study with a combined purpose, or in independent studies. In either case, the studies should be adequately powered to evaluate the BE, and independently, the comparative assessment of adhesion.
   - The applicant should follow FDA’s current thinking in the guidance “Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs” for the design and conduct of the independent adhesion study or the combined study to evaluate both PK BE and adhesion.

3. **Type of study:** Skin irritation and sensitization study  
   **Design:** Randomized, evaluator-blinded, within-subject repeat in vivo  
   **Strength:** 0.05;0.14 mg/24 hr or 0.05;0.25 mg/24 hr  
   **Subjects:** Non-smoking, postmenopausal women with no contraindication to estrogen therapy

   **Additional comments:**
   - All test articles (i.e., 0.05;0.14 mg/24 hr or 0.05;0.25 mg/24 hr test product\(^1\), 0.05;0.14 mg/24 hr or 0.05;0.25 mg/24 hr RLD product, optional vehicle TDS\(^2\) and

\(^1\) The test product evaluated should be the actual TDS to be marketed.
optional negative control\(^3\)) should be applied simultaneously to each subject at different positions on an application site recommended in the approved labeling for the RLD product.

- Sequential TDS applications should be made to the same application site every 84 hours for a total of 21 consecutive days. The TDS applied on Day 18 should be removed on Day 22.

- The applicant should follow FDA’s current thinking in the guidance “Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs” for the design and conduct of the skin irritation and sensitization study.

---

**Additional comments relating to all studies:**

In addition to the recommendations in the general guidances referenced above, and the product specific recommendations related to the individual studies, the following product specific recommendations should be considered.

- As a safety precaution, the subject’s seated blood pressure should be evaluated at all visits.

- Inclusion Criteria (the applicant may add additional criteria):
  a. Non-smoking, postmenopausal female subjects with no contraindication to estrogen therapy. “Postmenopausal” is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  b. Baseline systolic blood pressure should be no greater than 140 mm Hg and diastolic blood pressure no greater than 80 mm Hg.
  c. Subjects >40 years have documentation of a negative screening mammogram (obtained at screening or within 9 months of study enrollment) and a normal clinical breast examination prior to enrollment in study.
  d. Subjects with an intact uterus have baseline vaginal ultrasonography demonstrating inactive endometrial lining with endometrial thickness less than 4 mm.

- Exclusion Criteria (the applicant may add additional criteria):
  a. Male subject.

\(^2\) The optional vehicle TDS should contain all of the inactive ingredients in the test product and be identical to the test product in every manner except for the absence of the active ingredients.

\(^3\) An example of the optional negative control treatment is an occlusion cover or device with normal saline applied on a polyester pad under the cover or within the device chamber.
b. Premenopausal, perimenopausal, pregnant or lactating subject.

c. Undiagnosed abnormal genital bleeding.

d. Known, suspected, or history of breast cancer.

e. Known or suspected estrogen-dependent neoplasia.

f. History of endometrial cancer or risk factors for endometrial cancer.

g. Subject with tobacco use or body mass index (BMI) ≥90.

h. Active deep venous thrombosis, pulmonary embolism, or a history of these conditions.

i. High risk of venous thrombosis (VTE) or arterial thrombosis (ATE).

j. Active arterial thromboembolic disease (e.g., stroke and myocardial infarction), or a history of these conditions.

k. Anaphylactic reaction or angioedema with the RLD product.

l. Liver impairment or disease.

m. Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders.

n. History of cholestatic jaundice, hypertension, coronary heart disease or other serious heart problems, diabetes, hypercholesterolemia, hypercalcemia, hypoparathyroidism, hypertriglyceridemia, systemic lupus erythematosus, renal impairment, residual endometriosis post-hysterectomy, asthma, epilepsy, migraine, porphyria, hepatic hemangiomas.

o. History of narcotic abuse, drug abuse or alcoholism.

p. Within 6 months prior to dosing, estrogen pellet therapy or progestin injectable drug therapy.

q. Within 3 months prior to dosing, progestin implants and estrogen alone injectable drug therapy.

r. Within 8 weeks prior to dosing, oral estrogen and/or oral or intrauterine progestin therapy.

s. Within 4 weeks prior to dosing, transdermal estrogen alone or transdermal estrogen/progestin products.

t. Within 1 week prior to dosing, vaginal hormonal products (rings, creams, gels).

u. Within 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

v. Taking thyroid hormone replacement therapy.

w. Taking inducers of CYP3A4 such as St. John’s wort, anticonvulsants, phenylbutazone, rifampin, rifabutin, nevirapine and efavirenz.

x. Taking inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole,itraconazole, ritonavir, nelfinavir and grapefruit juice.
• A listing of the prescription and over-the-counter drug products that are contraindicated during the study should be provided, such as:
  
  a. Antihypertensives and pressor agents.
  
  b. Estrogens, other than study medication.